Trial Profile
A compassionate use study of RI-001 in Respiratory syncytial virus Infected Immunocompromised Persons
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Respiratory syncytial virus infections; Respiratory tract infections
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2016 New trial record